

# **The economic burden of chronic pain in the working population**

Anna Vavrovsky

May 15, 2013





## **Disclosure of interest**

I, Anna Vavrovsky, do not have a financial interest or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

# Perspectives and Costs



# Perspectives and Costs

**Patients**

**Payer**

**Society**

# Perspectives and Costs

**Patients**

**Payer**


**Society**

**Direct Costs**

Direct medical

Direct non-medical

# Direct costs as a function of pain score



# Perspectives and Costs

**Patients**

**Payer**

**Society**

**Direct Costs**

Direct medical  
Direct non-medical

# Perspectives and Costs

**Patients**

**Direct Costs**

Direct medical  
Direct non-medical

**Payer**

**Indirect Costs**

Losses or Gains of  
Productivity due to  
Morbidity and Mortality

**Society**



# Labour Force Participation






# Labour Force Participation

**65%** in general population without pain

**55%** in pain population

**45%** in population with severe pain

# Impact of pain relief on sickness absence



# Productivity at the workplace





# Productivity at the workplace

- Losses of productivity do not only include lost working time (absenteeism),




# Productivity at the workplace

- Losses of productivity do not only include lost working time (absenteeism),
- but also reduced productivity while the patient is present at the workplace (presenteeism)

# Productivity at the workplace

- Losses of productivity do not only include lost working time (absenteeism),
- but also reduced productivity while the patient is present at the workplace (presenteeism)



# Perspectives and Costs

**Patients**

**Direct Costs**

Direct medical  
Direct non-medical

**Payer**


**Indirect Costs**

Losses or Gains of  
Productivity due to  
Morbidity and Mortality


**Society**




# Perspectives and Costs



# Perspectives and Costs



# Utility gain associated with pain relief



# What goes into health economic analyses



# What goes into health economic analyses



- Epidemiology

# What goes into health economic analyses



- Epidemiology
- Stratification of patients

# What goes into health economic analyses



- Epidemiology
- Stratification of patients
- (Surrogate) endpoints

# What goes into health economic analyses



- Epidemiology
- Stratification of patients
- (Surrogate) endpoints
- Therapeutic alternatives



# What goes into health economic analyses



- Epidemiology
- Stratification of patients
- (Surrogate) endpoints
- Therapeutic alternatives
- Costs of delivering health care

# What goes into health economic analyses



- Epidemiology
- Stratification of patients
- (Surrogate) endpoints
- Therapeutic alternatives
- Costs of delivering health care
- Frequency and costs of adverse events

# What goes into health economic analyses




- Epidemiology
- Stratification of patients
- (Surrogate) endpoints
- Therapeutic alternatives
- Costs of delivering health care
- Frequency and costs of adverse events
- Costs of Non-Treatment

# What goes into health economic analyses



- Epidemiology
- Stratification of patients
- (Surrogate) endpoints
- Therapeutic alternatives
- Costs of delivering health care
- Frequency and costs of adverse events
- Costs of Non-Treatment



# Upstream Investment to Prevent Downstream Cost



# Upstream Investment to Prevent Downstream Cost



# Upstream Investment to Prevent Downstream Cost



# Upstream Investment to Prevent Downstream Cost





# Upstream Investment to Prevent Downstream Cost



# Upstream Investment to Prevent Downstream Cost



# Upstream Investment to Prevent Downstream Cost





[anna.vavrovsky@valueinhealth.com](mailto:anna.vavrovsky@valueinhealth.com)

+43 (0)1 9971 011-0

+43 (0)699 1977 0001